BD2 domain selective BET inhibitor

oral efficacy in 3 inflammation models

from SBDD of a BD2-selective HTS hit

Science, Mar. 19, 2020

GlaxoSmithKline, Stevenage, UK

Structure of pan-BD2 inhibitor GSK620

GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: